Compare Revvity Inc (RVTY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs S&P Global Inc — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while S&P Global Inc trades at $419.2 (market cap $126.56B). The key difference: S&P Global Inc is far larger — about 8.9× Revvity Inc's market cap, and S&P Global Inc pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| RVTY | SPGI | |
|---|---|---|
Market Cap | $14.18B | $126.56B |
Sector | Technology | Financials |
52-Week High | $130.94 | $522.21 |
52-Week Low | $82.26 | $370.42 |
Enterprise Value | $16.50B | $138.05B |
Dividend Yield | 0.22% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
SPGI trades at $429.31, down 3.2% over 24h, with a bullish technical signal and strong fundamentals including a 30.54% net income margin and consistent earnings beats. Recent news highlights strategic acquisitions and a focus on AI-resistant businesses, while analyst consensus remains strongly positive with an 85.7% buy rating.
Outlook is favorable due to high profitability and growth initiatives, but risks include rising debt levels and market sensitivity. The stock offers upside to the $523.20 consensus target, supported by institutional interest and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
